Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The ultimate goal is to improve our understanding of the pathophysiology and resistance to
effective treatment of sleep disordered breathing in patients with heart failure, with a
focus on selecting patients that will benefit specifically from acetazolamide treatment.
The study addresses three primary hypotheses: 1) Acetazolamide treatment will reduce the
apnea-hypopnea index and improve markers of heart-failure severity in heart-failure patients
with sleep apnea. 2) Acetazolamide will provide the greatest improvement in patients with the
most severe ventilatory control instability (strongest chemoreflex response to carbon
dioxide; highest loop gain). 3) Acetazolamide will act primarily via stabilizing ventilatory
control (reducing loop gain), rather than via improvement to upper airway anatomy, pulmonary
congestion, and cardiac function.
Phase:
N/A
Details
Lead Sponsor:
David Andrew Wellman
Collaborators:
American Heart Association National Institutes of Health (NIH)